Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Hartmut Weiler PhD

Associate Professor

Institution: Medical College of Wisconsin
Department: Physiology
Program: Genetics

Member of the Cancer Center


  • TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. (Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Weiler H, Aster RH, Hessner MJ, Hu J, Williams CB, Shi Q) Blood Adv 2016 Dec 13;1(2):139-151 PMID: 28164173 PMCID: PMC5288643 02/07/2017
  • High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis. (Lin C, von der Thüsen J, Isermann B, Weiler H, van der Poll T, Borensztajn K, Spek CA) J Cell Mol Med 2016 Nov;20(11):2029-2035 PMID: 27295971 PMCID: PMC5082406 10/27/2016
  • Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway. (Hu W, Zhang W, Chen Y, Rana U, Teng RJ, Duan Y, Liu Z, Zhao B, Foeckler J, Weiler H, Kallinger RE, Thomas MJ, Zhang K, Han J, Miao QR) Hepatology 2016 Nov;64(5):1559-1576 PMID: 27480224 PMCID: PMC5074877 10/22/2016
  • Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. (Baumgartner CK, Mattson JG, Weiler H, Shi Q, Montgomery RR) J Thromb Haemost 2017 Jan;15(1):98-109 PMID: 27496751 PMCID: PMC5280575 08/09/2016
  • Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice. (Rana U, Liu Z, Kumar SN, Zhao B, Hu W, Bordas M, Cossette S, Szabo S, Foeckler J, Weiler H, Chrzanowska-Wodnicka M, Holtz ML, Misra RP, Salato V, North PE, Ramchandran R, Miao QR) Dev Biol 2016 Feb 15;410(2):190-201 PMID: 26746789 PMCID: PMC4767500 01/10/2016
  • Myozap Deficiency Promotes Adverse Cardiac Remodeling via Differential Regulation of Mitogen-activated Protein Kinase/Serum-response Factor and β-Catenin/GSK-3β Protein Signaling. (Rangrez AY, Eden M, Poyanmehr R, Kuhn C, Stiebeling K, Dierck F, Bernt A, Lüllmann-Rauch R, Weiler H, Kirchof P, Frank D, Frey N) J Biol Chem 2016 Feb 19;291(8):4128-43 PMID: 26719331 PMCID: PMC4759188 01/01/2016
  • Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay. (Baumgartner CK, Zhang G, Kuether EL, Weiler H, Shi Q, Montgomery RR) J Thromb Haemost 2015 Dec;13(12):2210-9 PMID: 26453193 PMCID: PMC4715732 10/11/2015
  • Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. (Liang HP, Kerschen EJ, Basu S, Hernandez I, Zogg M, Jia S, Hessner MJ, Toso R, Rezaie AR, Fernández JA, Camire RM, Ruf W, Griffin JH, Weiler H) Blood 2015 Nov 19;126(21):2415-23 PMID: 26341257 PMCID: PMC4653768 09/06/2015
  • A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. (Ellery PE, Maroney SA, Cooley BC, Luyendyk JP, Zogg M, Weiler H, Mast AE) Blood 2015 Jun 25;125(26):4078-84 PMID: 25954015 PMCID: PMC4481595 05/09/2015
  • Thrombomodulin contributes to gamma tocotrienol-mediated lethality protection and hematopoietic cell recovery in irradiated mice. (Pathak R, Shao L, Ghosh SP, Zhou D, Boerma M, Weiler H, Hauer-Jensen M) PLoS One 2015;10(4):e0122511 PMID: 25860286 PMCID: PMC4393275 04/11/2015
  • Quantitative changes in Gimap3 and Gimap5 expression modify mitochondrial DNA segregation in mice. (Jokinen R, Lahtinen T, Marttinen P, Myöhänen M, Ruotsalainen P, Yeung N, Shvetsova A, Kastaniotis AJ, Hiltunen JK, Öhman T, Nyman TA, Weiler H, Battersby BJ) Genetics 2015 May;200(1):221-35 PMID: 25808953 PMCID: PMC4423365 03/27/2015
  • EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. (Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, Jia S, Hessner MJ, Griffin JH, Ruf W, Weiler H) Blood 2015 Apr 30;125(18):2845-54 PMID: 25733582 PMCID: PMC4424632 03/04/2015
  • Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. (Kerschen E, Hernandez I, Zogg M, Maas M, Weiler H) J Thromb Haemost 2015 Jun;13(6):1073-80 PMID: 25690763 PMCID: PMC4542152 02/19/2015
  • Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation. (Dinarvand P, Hassanian SM, Weiler H, Rezaie AR) Blood 2015 Feb 19;125(8):1339-48 PMID: 25575539 PMCID: PMC4335085 01/13/2015
  • Sucrose non-fermenting related kinase enzyme is essential for cardiac metabolism. (Cossette SM, Gastonguay AJ, Bao X, Lerch-Gaggl A, Zhong L, Harmann LM, Koceja C, Miao RQ, Vakeel P, Chun C, Li K, Foeckler J, Bordas M, Weiler H, Strande J, Palecek SP, Ramchandran R) Biol Open 2014 Dec 12;4(1):48-61 PMID: 25505152 PMCID: PMC4295165 12/17/2014
  • Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia. (de Boer JD, Kager LM, Roelofs JJ, Meijers JC, de Boer OJ, Weiler H, Isermann B, van 't Veer C, van der Poll T) BMC Infect Dis 2014 Nov 04;14:559 PMID: 25366058 PMCID: PMC4228088 11/05/2014
  • A thrombomodulin mutation that impairs active protein C generation is detrimental in severe pneumonia-derived gram-negative sepsis (melioidosis). (Kager LM, Wiersinga WJ, Roelofs JJ, de Boer OJ, Weiler H, van 't Veer C, van der Poll T) PLoS Negl Trop Dis 2014 Apr;8(4):e2819 PMID: 24762740 PMCID: PMC3998929 04/26/2014
  • Inflammation-associated activation of coagulation and immune regulation by the protein C pathway. (Weiler H) Thromb Res 2014 May;133 Suppl 1:S32-4 PMID: 24759138 PMCID: PMC4060429 04/25/2014
  • A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. (Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR) Blood 2014 Jun 12;123(24):3706-13 PMID: 24705491 PMCID: PMC4055921 04/08/2014
  • Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. (Yokota N, Zarpellon A, Chakrabarty S, Bogdanov VY, Gruber A, Castellino FJ, Mackman N, Ellies LG, Weiler H, Ruggeri ZM, Ruf W) J Thromb Haemost 2014 Jan;12(1):71-81 PMID: 24175924 PMCID: PMC3947224 11/02/2013
  • Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. (Borissoff JI, Otten JJ, Heeneman S, Leenders P, van Oerle R, Soehnlein O, Loubele ST, Hamulyák K, Hackeng TM, Daemen MJ, Degen JL, Weiler H, Esmon CT, van Ryn J, Biessen EA, Spronk HM, ten Cate H) PLoS One 2013;8(2):e55784 PMID: 23409043 PMCID: PMC3567111 02/15/2013
  • Thrombomodulin regulates keratinocyte differentiation and promotes wound healing. (Cheng TL, Wu YT, Lai CH, Kao YC, Kuo CH, Liu SL, Hsu YY, Chen PK, Cho CF, Wang KC, Lin WL, Chang BI, Chen CM, Weiler H, Shi GY, Wu HL) J Invest Dermatol 2013 Jun;133(6):1638-45 PMID: 23321922 01/17/2013
  • Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. (Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP, Fernández JÁ, Cancelas JA, Ryan MA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C, Weiler H, Hauer-Jensen M) Nat Med 2012 Jul;18(7):1123-9 PMID: 22729286 PMCID: PMC3491776 06/26/2012
  • Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. (Vicente CP, Weiler H, Di Cera E, Tollefsen DM) Thromb Res 2012 Oct;130(4):646-8 PMID: 22178578 PMCID: PMC3461961 12/20/2011
  • Multiple receptor-mediated functions of activated protein C. (Weiler H) Hamostaseologie 2011 Aug;31(3):185-95 PMID: 21826371 08/10/2011
  • Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. (Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS) Blood 2011 Sep 08;118(10):2889-95 PMID: 21788337 PMCID: PMC3172805 07/27/2011
  • Critical role for Gimap5 in the survival of mouse hematopoietic stem and progenitor cells. (Chen Y, Yu M, Dai X, Zogg M, Wen R, Weiler H, Wang D) J Exp Med 2011 May 09;208(5):923-35 PMID: 21502331 PMCID: PMC3092340 04/20/2011
  • Myospryn is a calcineurin-interacting protein that negatively modulates slow-fiber-type transformation and skeletal muscle regeneration. (Kielbasa OM, Reynolds JG, Wu CL, Snyder CM, Cho MY, Weiler H, Kandarian S, Naya FJ) FASEB J 2011 Jul;25(7):2276-86 PMID: 21427212 PMCID: PMC3114531 03/24/2011
  • Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. (Kerschen E, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernandez JA, Griffin JH, Huettner CS, Castellino FJ, Weiler H) J Clin Invest 2010 Sep;120(9):3167-78 PMID: 20714108 PMCID: PMC2929901 08/18/2010
  • Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. (Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR) Blood 2010 Oct 21;116(16):3049-57 PMID: 20606161 PMCID: PMC2974610 07/08/2010
  • Factor V Leiden mutation enhances fibrin formation and dissolution in vivo in a human endotoxemia model. (Elmas E, Suvajac N, Jilma B, Weiler H, Borggrefe M, Dempfle CE) Blood 2010 Aug 05;116(5):801-5 PMID: 20410502 04/23/2010
  • Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin. (Starr ME, Ueda J, Takahashi H, Weiler H, Esmon CT, Evers BM, Saito H) Blood 2010 Jun 10;115(23):4886-93 PMID: 20348393 PMCID: PMC2890181 03/30/2010
  • Regulation of inflammation by the protein C system. (Weiler H) Crit Care Med 2010 Feb;38(2 Suppl):S18-25 PMID: 20083909 01/30/2010
  • Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. (Seehaus S, Shahzad K, Kashif M, Vinnikov IA, Schiller M, Wang H, Madhusudhan T, Eckstein V, Bierhaus A, Bea F, Blessing E, Weiler H, Frommhold D, Nawroth PP, Isermann B) Circulation 2009 Sep 01;120(9):774-84 PMID: 19687358 08/19/2009
  • Modulation of sepsis outcome with variants of activated protein C. (Weiler H, Kerschen E) J Thromb Haemost 2009 Jul;7 Suppl 1:127-31 PMID: 19630784 07/28/2009
  • Knockout rats via embryo microinjection of zinc-finger nucleases. (Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A, Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M, Schilling R, Foeckler J, Kalloway S, Weiler H, Ménoret S, Anegon I, Davis GD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jacob HJ, Buelow R) Science 2009 Jul 24;325(5939):433 PMID: 19628861 PMCID: PMC2831805 07/25/2009
  • Fibrinogen alpha and gamma genes and factor VLeiden in children with thromboembolism: results from 2 family-based association studies. (Nowak-Göttl U, Weiler H, Hernandez I, Thedieck S, Seehafer T, Schulte T, Stoll M) Blood 2009 Aug 27;114(9):1947-53 PMID: 19515723 06/12/2009
  • Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. (Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernández JA, Yang XV, Riewald M, Weiler H, Ruggeri ZM, Griffin JH) Blood 2009 Jun 04;113(23):5970-8 PMID: 19244160 PMCID: PMC2700330 02/27/2009
  • Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. (Niessen F, Furlan-Freguia C, Fernández JA, Mosnier LO, Castellino FJ, Weiler H, Rosen H, Griffin JH, Ruf W) Blood 2009 Mar 19;113(12):2859-66 PMID: 19141861 PMCID: PMC2661868 01/15/2009
  • Caveolin-1-dependent apoptosis induced by fibrin degradation products. (Guo YH, Hernandez I, Isermann B, Kang TB, Medved L, Sood R, Kerschen EJ, Holyst T, Mosesson MW, Weiler H) Blood 2009 Apr 30;113(18):4431-9 PMID: 19074731 PMCID: PMC2676096 12/17/2008
  • Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence. (Mosesson MW, Cooley BC, Hernandez I, Diorio JP, Weiler H) J Thromb Haemost 2009 Jan;7(1):102-10 PMID: 18983496 11/06/2008
  • Calsarcin-2 deficiency increases exercise capacity in mice through calcineurin/NFAT activation. (Frey N, Frank D, Lippl S, Kuhn C, Kögler H, Barrientos T, Rohr C, Will R, Müller OJ, Weiler H, Bassel-Duby R, Katus HA, Olson EN) J Clin Invest 2008 Nov;118(11):3598-608 PMID: 18846255 PMCID: PMC2564612 10/11/2008
  • Tracing the molecular pathogenesis of antiphospholipid syndrome. (Weiler H) J Clin Invest 2008 Oct;118(10):3276-8 PMID: 18802489 PMCID: PMC2542859 09/20/2008
  • Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5. (Schulteis RD, Chu H, Dai X, Chen Y, Edwards B, Haribhai D, Williams CB, Malarkannan S, Hessner MJ, Glisic-Milosavljevic S, Jana S, Kerschen EJ, Ghosh S, Wang D, Kwitek AE, Lernmark A, Gorski J, Weiler H) Blood 2008 Dec 15;112(13):4905-14 PMID: 18796632 PMCID: PMC2597598 09/18/2008
  • Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. (Weiler H, Ruf W) Curr Opin Hematol 2008 Sep;15(5):487-93 PMID: 18695372 PMCID: PMC2742321 08/13/2008
  • Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. (Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR) Blood 2008 Oct 01;112(7):2713-21 PMID: 18495954 PMCID: PMC2556608 05/23/2008
  • Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. (Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H) Blood 2008 Aug 01;112(3):585-91 PMID: 18490515 PMCID: PMC2481555 05/21/2008
  • Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. (Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP) Nat Med 2007 Nov;13(11):1349-58 PMID: 17982464 11/06/2007
  • Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition. (Maroney SA, Cooley BC, Sood R, Weiler H, Mast AE) J Thromb Haemost 2008 Jan;6(1):111-7 PMID: 17973652 PMCID: PMC3646640 11/02/2007
  • Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. (Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H) J Exp Med 2007 Oct 01;204(10):2439-48 PMID: 17893198 PMCID: PMC2118455 09/26/2007
  • Endothelial protein C receptor: location...with a pool! (Weiler H) J Thromb Haemost 2007 Jul;5(7):1391-3 PMID: 17456191 04/26/2007
  • Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. (Sood R, Zogg M, Westrick RJ, Guo YH, Kerschen EJ, Girardi G, Salmon JE, Coughlin SR, Weiler H) J Exp Med 2007 May 14;204(5):1049-56 PMID: 17438064 PMCID: PMC2118565 04/18/2007
  • Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. (Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR) J Clin Invest 2006 Jul;116(7):1974-82 PMID: 16823491 PMCID: PMC1483176 07/11/2006
  • Myospryn is a direct transcriptional target for MEF2A that encodes a striated muscle, alpha-actinin-interacting, costamere-localized protein. (Durham JT, Brand OM, Arnold M, Reynolds JG, Muthukumar L, Weiler H, Richardson JA, Naya FJ) J Biol Chem 2006 Mar 10;281(10):6841-9 PMID: 16407236 01/13/2006
  • Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. (Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H) Blood 2006 Apr 15;107(8):3173-80 PMID: 16380449 PMCID: PMC1895751 12/29/2005
  • Platelet PECAM-1 inhibits thrombus formation in vivo. (Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM) Blood 2006 Jan 15;107(2):535-41 PMID: 16166583 PMCID: PMC1895610 09/17/2005
  • Thrombophilia and pregnancy failure: feto-maternal interactions in the vascular bed of the placenta. (Sood R, Kalloway S, Mast AE, Weiler H) Thromb Res 2005 Feb;115 Suppl 1:92-4 PMID: 15790167 03/26/2005
  • Restricted inactivation of serum response factor to the cardiovascular system. (Miano JM, Ramanan N, Georger MA, de Mesy Bentley KL, Emerson RL, Balza RO Jr, Xiao Q, Weiler H, Ginty DD, Misra RP) Proc Natl Acad Sci U S A 2004 Dec 07;101(49):17132-7 PMID: 15569937 PMCID: PMC535359 12/01/2004
  • Mouse models of thrombosis: thrombomodulin. (Weiler H) Thromb Haemost 2004 Sep;92(3):467-77 PMID: 15351842 09/08/2004
  • Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. (Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H, Isermann BH) J Thromb Haemost 2004 Aug;2(8):1368-79 PMID: 15304043 08/12/2004
  • Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. (Weiler H, Kerlin B, Lytle MC) Crit Care Med 2004 May;32(5 Suppl):S233-8 PMID: 15118524 05/01/2004
  • Cause-effect relation between hyperfibrinogenemia and vascular disease. (Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H) Blood 2004 Mar 01;103(5):1728-34 PMID: 14615369 11/15/2003
  • Thrombomodulin. (Weiler H, Isermann BH) J Thromb Haemost 2003 Jul;1(7):1515-24 PMID: 12871287 07/23/2003
  • Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. (Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF) Blood 2003 Nov 01;102(9):3085-92 PMID: 12869495 07/19/2003
  • Embryogenesis and gene targeting of coagulation factors in mice. (Sood R, Weiler H) Best Pract Res Clin Haematol 2003 Jun;16(2):169-81 PMID: 12763485 05/24/2003
  • The thrombomodulin-protein C system is essential for the maintenance of pregnancy. (Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H) Nat Med 2003 Mar;9(3):331-7 PMID: 12579195 02/13/2003
  • The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. (Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G) J Exp Med 2002 Sep 02;196(5):565-77 PMID: 12208873 PMCID: PMC2193995 09/05/2002
  • Mouse models in coagulation. (Hogan KA, Weiler H, Lord ST) Thromb Haemost 2002 Apr;87(4):563-74 PMID: 12008936 05/15/2002
  • Expression of human smooth muscle calponin in transgenic mice revealed with a bacterial artificial chromosome. (Miano JM, Kitchen CM, Chen J, Maltby KM, Kelly LA, Weiler H, Krahe R, Ashworth LK, Garcia E) Am J Physiol Heart Circ Physiol 2002 May;282(5):H1793-803 PMID: 11959645 04/18/2002
  • Characterization of a mouse model for thrombomodulin deficiency. (Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI) Arterioscler Thromb Vasc Biol 2001 Sep;21(9):1531-7 PMID: 11557684 09/15/2001
  • Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. (Isermann B, Hendrickson SB, Zogg M, Wing M, Cummiskey M, Kisanuki YY, Yanagisawa M, Weiler H) J Clin Invest 2001 Aug;108(4):537-46 PMID: 11518727 PMCID: PMC209404 08/24/2001
  • An efficient method to successively introduce transgenes into a given genomic locus in the mouse. (Zhao R, Fahs SA, Weiler H, Duncan SA) BMC Dev Biol 2001;1:10 PMID: 11430765 PMCID: PMC33517 06/30/2001
  • Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. (Isermann B, Hendrickson SB, Hutley K, Wing M, Weiler H) Development 2001 Mar;128(6):827-38 PMID: 11222138 02/27/2001
  • The basic helix-loop-helix transcription factor capsulin controls spleen organogenesis. (Lu J, Chang P, Richardson JA, Gan L, Weiler H, Olson EN) Proc Natl Acad Sci U S A 2000 Aug 15;97(17):9525-30 PMID: 10944221 PMCID: PMC16898 08/16/2000
  • Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. (Healy AM, Rayburn HB, Rosenberg RD, Weiler H) Proc Natl Acad Sci U S A 1995 Jan 31;92(3):850-4 PMID: 7846065 PMCID: PMC42718 01/31/1995
  • Last update: 01/26/2017
    jenkins-FCD Prod-130 96200611f8481f0aa4f84230b11dd74d063847a3